logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9879030 B1

PDFFull Text
Date of Patent:
Jan. 30, 2018

Filed:

May. 09, 2012

Gpr17 receptor modulators

Applicants:

Maria Pia Abbracchio, Milan, IT;

Mario Alberto Battaglia, Genoa, IT;

Ivano Eberini, Milan, IT;

Marta Fumagalli, Milan, IT;

Chiara Parravicini, Milan, IT;

Cristina Sensi, Milan, IT;

Paola Zaratin, Genoa, IT;

Inventors:

Maria Pia Abbracchio, Milan, IT;

Mario Alberto Battaglia, Genoa, IT;

Ivano Eberini, Milan, IT;

Marta Fumagalli, Milan, IT;

Chiara Parravicini, Milan, IT;

Cristina Sensi, Milan, IT;

Paola Zaratin, Genoa, IT;

Assignees:

UNIVERSITA′ DEGLI STUDI DI MILANO, Milan, IT;

FONDAZIONE ITALIANA SCLEROSI MULTIPLA—FISM ONLUS, Genoa, IT;

Attorney:

Robert E. Alderson, Jr.

Primary Examiner:

Bruck Kifle

Int. Cl.
CPC ...
C07D 243/12 (2006.01); C07D 249/12 (2006.01); C07D 487/04 (2006.01); A61K 31/4196 (2006.01); A61K 31/551 (2006.01); C07D 495/14 (2006.01); A61K 31/454 (2006.01); A61K 31/4725 (2006.01); A61K 31/4741 (2006.01); A61K 31/519 (2006.01); A61K 31/5513 (2006.01); A61K 45/06 (2006.01); C07D 243/16 (2006.01); C07D 491/056 (2006.01);
U.S. Cl.
CPC ...
C07D 495/14 (2013.01); A61K 31/4196 (2013.01); A61K 31/454 (2013.01); A61K 31/4725 (2013.01); A61K 31/4741 (2013.01); A61K 31/519 (2013.01); A61K 31/5513 (2013.01); A61K 45/06 (2013.01); C07D 243/12 (2013.01); C07D 243/16 (2013.01); C07D 249/12 (2013.01); C07D 487/04 (2013.01); C07D 491/056 (2013.01);
Abstract

Chemical compounds are provided which act on GPR17 receptors and are useful in the treatment or amelioration of chronic and/or acute neurodegenerative diseases, such as multiple sclerosis, inflammatory diseases, pathologies involving the immune system, cardiovascular diseases, and renal diseases.

Find Patent Forward Citations

Loading…